{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:53:40Z","timestamp":1776092020678,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,7,12]],"date-time":"2007-07-12T00:00:00Z","timestamp":1184198400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Duchenne muscular dystrophy results from mutation of the dystrophin gene, causing skeletal and cardiac muscle loss of function. The mdx mouse model of Duchenne muscular dystrophy is widely utilized to evaluate the potential of therapeutic regimens to modulate the loss of skeletal muscle function associated with dystrophin mutation. Importantly, progressive loss of diaphragm function is the most consistent striated muscle effect observed in the mdx mouse model, which is the same as in patients suffering from Duchenne muscular dystrophy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Using the mdx mouse model, we have evaluated the effect that corticotrophin releasing factor 2 receptor (CRF2R) agonist treatment has on diaphragm function, morphology and gene expression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We have observed that treatment with the potent CRF2R-selective agonist PG-873637 prevents the progressive loss of diaphragm specific force observed during aging of mdx mice. In addition, the combination of PG-873637 with glucocorticoids not only prevents the loss of diaphragm specific force over time, but also results in recovery of specific force. Pathological analysis of CRF2R agonist-treated diaphragm muscle demonstrates that treatment reduces fibrosis, immune cell infiltration, and muscle architectural disruption. Gene expression analysis of CRF2R-treated diaphragm muscle showed multiple gene expression changes including globally decreased immune cell-related gene expression, decreased extracellular matrix gene expression, increased metabolism-related gene expression, and, surprisingly, modulation of circadian rhythm gene expression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Together, these data demonstrate that CRF2R activation can prevent the progressive degeneration of diaphragm muscle associated with dystrophin gene mutation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1741-7015-5-18","type":"journal-article","created":{"date-parts":[[2007,7,12]],"date-time":"2007-07-12T18:13:36Z","timestamp":1184264016000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice"],"prefix":"10.1186","volume":"5","author":[{"given":"Richard T","family":"Hinkle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank R","family":"Lefever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth T","family":"Dolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah L","family":"Reichart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jefferey A","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn E","family":"Gropp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert I","family":"Thacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey P","family":"Demuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula J","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan A","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex R","family":"Varbanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J","family":"Isfort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,7,12]]},"reference":[{"key":"119_CR1","first-page":"1133","volume-title":"Myology","author":"AG Engel","year":"1994","unstructured":"Engel AG, Yamamoto M, Fischbeck KH: Dystrophinopathies. Myology. Edited by: Engel AG, Franzini-Armstrong C. 1994, Columbus, OH: McGraw-Hill, 1133-1187."},{"key":"119_CR2","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/sj.embor.7400221","volume":"5","author":"KJ Nowak","year":"2004","unstructured":"Nowak KJ, Davies KE: Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Reports. 2004, 5: 872-876. 10.1038\/sj.embor.7400221.","journal-title":"EMBO Reports"},{"key":"119_CR3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1152\/physrev.00028.2001","volume":"82","author":"DJ Blake","year":"2002","unstructured":"Blake DJ, Weir A, Newey SE, Davies KE: Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002, 82: 291-329.","journal-title":"Physiol Rev"},{"key":"119_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nrd1085","volume":"2","author":"TS Khurana","year":"2003","unstructured":"Khurana TS, Davies KE: Pharmacological strategies for muscular dystrophy. Nat Rev Drug Disc. 2003, 2: 379-390. 10.1038\/nrd1085.","journal-title":"Nat Rev Drug Disc"},{"key":"119_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.molmed.2004.08.007","volume":"10","author":"G Cossu","year":"2004","unstructured":"Cossu G, Sampaolesi M: New therapies for muscular dystrophy: cautious optimism. Trends Mol Med. 2004, 10: 516-520. 10.1016\/j.molmed.2004.08.007.","journal-title":"Trends Mol Med"},{"key":"119_CR6","doi-asserted-by":"publisher","first-page":"S162","DOI":"10.1016\/S0960-8966(02)00101-3","volume":"1","author":"F Muntoni","year":"2002","unstructured":"Muntoni F, Fisher I, Morgan JE, Abraham D: Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research. Neuromuscul Disord. 2002, 1: S162-S165. 10.1016\/S0960-8966(02)00101-3.","journal-title":"Neuromuscul Disord"},{"key":"119_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00109-003-0484-1","volume":"82","author":"S Bogdanovich","year":"2004","unstructured":"Bogdanovich S, Perkins KJ, Krag TOB, Khurana TS: Therapeutics for Duchenne muscular dystrophy: current approaches and future directions. J Mol Med. 2004, 82: 102-115. 10.1007\/s00109-003-0484-1.","journal-title":"J Mol Med"},{"key":"119_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0959-437X(02)00309-X","volume":"12","author":"M Durbeej","year":"2002","unstructured":"Durbeej M, Campbell KP: Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. Curr Opin Genet Dev. 2002, 12: 349-361. 10.1016\/S0959-437X(02)00309-X.","journal-title":"Curr Opin Genet Dev"},{"key":"119_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1046\/j.1365-2613.2003.00354.x","volume":"84","author":"CA Collins","year":"2003","unstructured":"Collins CA, Morgan JE: Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies. Int J Exp Pathol. 2003, 84: 165-172. 10.1046\/j.1365-2613.2003.00354.x.","journal-title":"Int J Exp Pathol"},{"key":"119_CR10","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/mus.880151008","volume":"15","author":"EE Dupont-Versteegden","year":"1992","unstructured":"Dupont-Versteegden EE, McCarter RJ: Differential expression of muscular dystrophy in diaphragm versus hindlimb muscles of mdx mice. Muscle Nerve. 1992, 15: 1105-1110. 10.1002\/mus.880151008.","journal-title":"Muscle Nerve"},{"key":"119_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/0960-8966(93)90098-5","volume":"3","author":"JP Louboutin","year":"1993","unstructured":"Louboutin JP, Fichter-Gagnepain V, Thaon E, Fardeau M: Morphometric analysis of mdx diaphragm muscle fibres: comparison with hindlimb muscles. Neuromuscul Disord. 1993, 3: 463-469. 10.1016\/0960-8966(93)90098-5.","journal-title":"Neuromuscul Disord"},{"key":"119_CR12","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/352536a0","volume":"352","author":"HH Stedman","year":"1991","unstructured":"Stedman HH, Sweeney HL, Leferovich JM, Sladky JT, Kelly AM: The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature. 1991, 352: 536-538. 10.1038\/352536a0.","journal-title":"Nature"},{"key":"119_CR13","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.1210\/en.2003-0271","volume":"144","author":"RT Hinkle","year":"2003","unstructured":"Hinkle RT, Donnelly E, Cody DB, Bauer MB, Isfort RJ: Urocortin II treatment reduces skeletal muscle mass and function loss during atrophy and increases nonatrophying skeletal muscle mass and function. Endocrinology. 2003, 144: 4939-4946. 10.1210\/en.2003-0271.","journal-title":"Endocrinology"},{"key":"119_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10974-004-4088-3","volume":"25","author":"RT Hinkle","year":"2005","unstructured":"Hinkle RT, Donnelly E, Cody DB, Bauer MB, Sheldon RJ, Isfort RJ: Corticotropin releasing factor 2 receptor agonists reduce the denervation-induced loss of rat skeletal muscle mass and force and increase non-atrophying skeletal muscle mass and force. J Muscle Res Cell Motil. 2005, 25: 539-547. 10.1007\/s10974-004-4088-3.","journal-title":"J Muscle Res Cell Motil"},{"key":"119_CR15","doi-asserted-by":"publisher","first-page":"E889","DOI":"10.1152\/ajpendo.00081.2003","volume":"285","author":"RT Hinkle","year":"2003","unstructured":"Hinkle RT, Donnelly E, Cody DB, Samuelsson S, Lange JS, Bauer MB, Tarnopolsky M, Sheldon RJ, Coste SC, Tobar E, Stenzel-Poore MP, Isfort RJ: Activation of the CRF2 receptor modulates skeletal muscle mass under physiological and pathological conditions. Am J Physiol Endocrinol Metab. 2003, 285: E889-E898.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"119_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1021\/jm049490m","volume":"13","author":"RJ Isfort","year":"2005","unstructured":"Isfort RJ, Wang F, Tscheiner M, Donnelly E, Bauer MB, Lefever F, Hinkle RT, Mazur AW: Discovery of corticotropin releasing factor 2 receptor selective sauvagine analogues for treatment of skeletal muscle atrophy. J Med Chem. 2005, 13: 262-263. 10.1021\/jm049490m.","journal-title":"J Med Chem"},{"key":"119_CR17","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1021\/jm049883l","volume":"47","author":"AW Mazur","year":"2004","unstructured":"Mazur AW, Wang F, Tscheiner M, Donnelly E, Isfort RJ: Determinants of corticotrophin releasing factor receptor selectivity of corticotrophin releasing factor related peptides. J Med Chem. 2004, 47: 3450-3454. 10.1021\/jm049883l.","journal-title":"J Med Chem"},{"key":"119_CR18","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.peptides.2004.12.013","volume":"26","author":"AW Mazur","year":"2005","unstructured":"Mazur AW, Wang F, Tscheiner M, Donnelly E, Isfort RJ: Sauvagine analogs selective for corticotrophin releasing factor 2 receptor: effects of substitutions at positions 35 and 39 on CRFR selectivity. Peptides. 2005, 26: 887-891. 10.1016\/j.peptides.2004.12.013.","journal-title":"Peptides"},{"key":"119_CR19","first-page":"45","volume":"79","author":"MS Hudecki","year":"1993","unstructured":"Hudecki MS, Pollina CM, Granchelli JA, Daly MK, Byrnes T, Wang JC, Hsiao JC: Strength and endurance in the therapeutic evaluation of prednisolone-treated mdx mice. Res Commun Chem Pathol Pharmacol. 1993, 79: 45-60.","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"119_CR20","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1056\/NEJM198906153202405","volume":"320","author":"JR Mendell","year":"1989","unstructured":"Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, King W, Signore L, Pandya S, Florence J, Shierbecker J, Robison J, Kaiser K, Mandel S, Arfken C, Gilder B: Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med. 1989, 320: 1592-1597.","journal-title":"N Engl J Med"},{"key":"119_CR21","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/hmg\/9.7.1033","volume":"9","author":"M Yoshida","year":"2000","unstructured":"Yoshida M, Hama H, Ishikawa-Sakurai M, Imamura M, Mizuno Y, Araishi K, Wakabayashi-Takai E, Noguchi S, Sasaoka T, Ozawa E: Biochemical evidence for association of dystrobrevin with sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy. Hum Mol Genet. 2000, 9: 1033-1040. 10.1093\/hmg\/9.7.1033.","journal-title":"Hum Mol Genet"},{"key":"119_CR22","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/S0002-9440(10)62333-4","volume":"166","author":"LJ Harcourt","year":"2005","unstructured":"Harcourt LJ, Holmes AG, Gregorevic P, Schertzer JD, Stupka N, Plant DR, Lynch GS: Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice. Am J Pathol. 2005, 166: 1131-1141.","journal-title":"Am J Pathol"},{"key":"119_CR23","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nrg1633","volume":"6","author":"D Bell-Pedersen","year":"2005","unstructured":"Bell-Pedersen D, Cassone VM, Earnest DJ, Golden SS, Hardin PE, Thomas TL, Zoran MJ: Circadian rhythms from multiple oscillators: lessons from diverse organisms. Nat Rev Genet. 2005, 6: 544-556. 10.1038\/nrg1633.","journal-title":"Nat Rev Genet"},{"key":"119_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/ng1504","volume":"37","author":"HR Ueda","year":"2005","unstructured":"Ueda HR, Hayashi S, Chen W, Sano M, Machida M, Shigeyoshi Y, Iino M, Hashimoto S: System-level identification of transcriptional circuits underlying mammalian circadian clocks. Nat Genet. 2005, 37: 187-192. 10.1038\/ng1504.","journal-title":"Nat Genet"},{"key":"119_CR25","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1046\/j.1365-2826.2003.01082.x","volume":"15","author":"GE Duffield","year":"2003","unstructured":"Duffield GE: DNA microarray analyses of circadian timing: the genomic basis of biological time. J Neuroendocrinol. 2003, 15: 991-1002. 10.1046\/j.1365-2826.2003.01082.x.","journal-title":"J Neuroendocrinol"},{"key":"119_CR26","doi-asserted-by":"publisher","first-page":"R61","DOI":"10.1186\/gb-2003-4-10-r61","volume":"4","author":"AC Zambon","year":"2003","unstructured":"Zambon AC, McDearmon EL, Salomonis N, Vranizan KM, Johansen KL, Adey D, Takahashi JS, Schambelan M, Conklin BR: Time- and exercise-dependent gene regulation in human skeletal muscle. Gen Biol. 2003, 4: R61-10.1186\/gb-2003-4-10-r61.","journal-title":"Gen Biol"},{"key":"119_CR27","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1126\/science.1108750","volume":"308","author":"FW Turek","year":"2005","unstructured":"Turek FW, Joshu C, Kohsaka A, Lin E, Ivanova G, McDearmon E, Laposky A, Losee-Olson S, Easton A, Jensen DR, Eckel RH, Takahashi JS, Bass J: Obesity and metabolic syndrome in circadian clock mutant mice. Science. 2005, 308: 1043-1045. 10.1126\/science.1108750.","journal-title":"Science"},{"key":"119_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev.biochem.71.090501.142857","volume":"71","author":"J Rutter","year":"2002","unstructured":"Rutter J, Reick M, McKnight SL: Metabolism and the control of circadian rhythm. Ann Rev Biochem. 2002, 71: 307-331. 10.1146\/annurev.biochem.71.090501.142857.","journal-title":"Ann Rev Biochem"},{"key":"119_CR29","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1126\/science.1060698","volume":"293","author":"J Rutter","year":"2001","unstructured":"Rutter J, Reick M, Wu LC, McKnight SL: Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science. 2001, 293: 510-514. 10.1126\/science.1060698.","journal-title":"Science"},{"key":"119_CR30","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.peptides.2004.01.008","volume":"25","author":"MA Pelleymounter","year":"2004","unstructured":"Pelleymounter MA, Joppa M, Ling N, Foster AC: Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides. 2004, 25: 659-666. 10.1016\/j.peptides.2004.01.008.","journal-title":"Peptides"},{"key":"119_CR31","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1126\/science.289.5488.2344","volume":"289","author":"A Balsalobre","year":"2000","unstructured":"Balsalobre A, Brown SA, Marcacci L, Tronche F, Kellendonk C, Reichardt HM, Schutz G, Schibler U: Resetting of circadian time in peripheral tissues by glucocorticoid signaling. Science. 2000, 289: 2344-2347. 10.1126\/science.289.5488.2344.","journal-title":"Science"},{"key":"119_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.brainres.2006.02.017","volume":"1083","author":"RL Gannon","year":"2006","unstructured":"Gannon RL, Millan MJ: The corticotrophin-releasing factor (CRF)(1) receptor antagonists CP154,526 and DMP695 inhibit light-induced phase advances of hamster circadian activity rhythms. Brain Res. 2006, 1083: 92-102. 10.1016\/j.brainres.2006.02.017.","journal-title":"Brain Res"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-5-18.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1741-7015-5-18\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1741-7015-5-18.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:55:16Z","timestamp":1630450516000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/1741-7015-5-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["119"],"URL":"https:\/\/doi.org\/10.1186\/1741-7015-5-18","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,12]]},"assertion":[{"value":"13 October 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"18"}}